UnitedHealth Group has remained a subject of active institutional attention heading into mid-2026. The company operates across managed care, pharmacy benefits, and health services segments, and continues to draw scrutiny amid a broader environment of elevated healthcare costs and regulatory developments. Recent briefings from late May and early June 2026 noted ongoing institutional focus on the name across these operational dimensions [Brief - 2026-06-01] [Brief - 2026-05-24].
As of 31 March 2026, UnitedHealth Group reported trailing twelve-month revenue of approximately $449.7 billion, representing year-over-year growth of approximately 1.96%. Net income on a TTM basis stood at approximately $12.8 billion, with a net margin of 2.85% and an operating margin of 4.19%. EPS growth on a year-over-year basis was 0.73%. The company held approximately $28.0 billion in cash against total debt of approximately $77.9 billion. The reported P/E ratio was 30.62, with a market capitalisation of approximately $369.2 billion [SEC 10-Q - UNH - 2026-03-31].
Insider activity in June 2026 recorded two transactions with a mixed net direction and a net value of zero, indicating no material net change in insider positioning [SEC Form 4 - UNH - 2026-06]. Institutional ownership changes were material and divergent. Citadel reduced its UNH position by 19% and Tiger Global reduced its position by 17%. Conversely, Millennium added 56% to its position, AQR Capital added 36%, and Soros Fund Management added 14% [SEC 13F - Citadel - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Tiger Global - Q1 2026] [SEC 13F - Soros Fund Mgmt - Q1 2026].
The broader macro environment as of the report date reflects a 10-year US Treasury yield of 4.55% and a 2-year yield of 4.17%, producing a normal yield curve spread of 38 basis points [FRED DGS10] [FRED DGS2]. This report was generated in response to material institutional position changes across multiple prominent filers during the most recent 13F reporting period.